

# SAFETY DATA SHEET



## Levamisole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

### Section 1: Identification

Product name : Levamisole / Oxclozanide Formulation

#### Manufacturer or supplier's details

Company : MSD

Address : 33 Whakatiki Street - Private Bag 908  
Upper Hutt - New Zealand

Telephone : 0800 800 543

Emergency telephone number : 0800 764 766 (0800 POISON)    0800 243 622 (0800  
CHEMCALL)

E-mail address : EHSDATASTEWARD@msd.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

---

### Section 2: Hazard identification

#### GHS Classification

Respiratory sensitisation : Category 1

Skin sensitisation : Category 1

Reproductive toxicity : Category 2

Specific target organ toxicity - : Category 2 (Central nervous system)  
single exposure (Oral)

Specific target organ toxicity - : Category 2 (Brain, Liver)  
repeated exposure

Specific target organ toxicity - : Category 2 (Blood, Testis)  
repeated exposure (Oral)

Hazardous to the aquatic environment - chronic hazard : Category 2

#### GHS label elements

**Levamisole / Oxclozanide Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
5360102-00013Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

Hazard pictograms



Signal word

: Danger

Hazard statements

: H317 May cause an allergic skin reaction.  
H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
H361d Suspected of damaging the unborn child.  
H371 May cause damage to organs (Central nervous system) if swallowed.  
H373 May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.  
H373 May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements

**Prevention:**

P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe mist or vapours.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.  
P284 Wear respiratory protection.

**Response:**

P302 + P352 IF ON SKIN: Wash with plenty of water.  
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P308 + P311 IF exposed or concerned: Call a POISON CENTER/ doctor.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.  
P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

# SAFETY DATA SHEET



## Levamisole / Oxyclozanide Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 5360102-00013 Date of last issue: 28.09.2024 Date of first issue: 19.12.2019

---

### Other hazards which do not result in classification

None known.

## Section 3: Composition/information on ingredients

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Concentration (% w/w)
Kaolin	1332-58-7	>= 1 < 10
oxyclozanide	2277-92-1	>= 2.5 < 10
levamisole hydrochloride	16595-80-5	>= 1 < 2.5
Citric acid	77-92-9	>= 1 < 10
Sodium metabisulphite	7681-57-4	>= 0.1 < 1

## Section 4: First-aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.  
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.

In case of eye contact : Thoroughly clean shoes before reuse.  
Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.  
Never give anything by mouth to an unconscious person.

Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.  
May cause allergy or asthma symptoms or breathing difficulties if inhaled.  
Suspected of damaging the unborn child.  
May cause damage to organs if swallowed.  
May cause damage to organs through prolonged or repeated exposure.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

## Section 5: Fire-fighting measures

Suitable extinguishing media : Water spray  
Alcohol-resistant foam

# SAFETY DATA SHEET



## Levamisole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Chlorine compounds  
Nitrogen oxides (NO<sub>x</sub>)

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Hazchem Code : 3Z

---

### Section 6: Accidental release measures

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Prevent spreading over a wide area (e.g. by containment or oil barriers).  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.  
Clean up remaining materials from spill with suitable absorbent.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

# SAFETY DATA SHEET



## Levamisole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

### Section 7: Handling and storage

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe mist or vapours.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents

---

### Section 8: Exposure controls/personal protection

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Kaolin	1332-58-7	WES-TWA	10 mg/m <sup>3</sup>	NZ OEL
		WES-TWA (Respirable dust)	2 mg/m <sup>3</sup>	NZ OEL
		TWA (Respirable particulate matter)	2 mg/m <sup>3</sup>	ACGIH
oxclozanide	2277-92-1	TWA	0.4 mg/m <sup>3</sup> (OEB 2)	Internal
levamisole hydrochloride	16595-80-5	TWA	20 µg/m <sup>3</sup> (OEB 3)	Internal

# SAFETY DATA SHEET



## Levamisole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

	Further information: Skin			
		Wipe limit	200 µg/100 cm <sup>2</sup>	Internal
Sodium metabisulphite	7681-57-4	WES-TWA	5 mg/m <sup>3</sup>	NZ OEL
	Further information: Skin sensitisier, Respiratory sensitisier			
		TWA	5 mg/m <sup>3</sup>	ACGIH

**Engineering measures**

- : Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip-less quick connections).  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.  
Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).  
Minimize open handling.

### Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks

Eye protection : Consider double gloving.  
Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.  
Use appropriate degowning techniques to remove potentially contaminated clothing.

### Section 9: Physical and chemical properties

Appearance : liquid

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

# SAFETY DATA SHEET



## Levamisole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	No data available
Evaporation rate	:	No data available
Flammability (solid, gas)	:	Not applicable
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity		
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics		
Particle size	:	Not applicable

---

## Section 10: Stability and reactivity

# SAFETY DATA SHEET



## Levamisole / Oxyclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

### Section 11: Toxicological information

Exposure routes	:	Inhalation
	:	Skin contact
	:	Ingestion
	:	Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg
	:	Method: Calculation method

#### Components:

##### **Kaolin:**

Acute oral toxicity	:	LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity	:	LD50 (Rat): > 5,000 mg/kg

##### **oxyclozanide:**

Acute oral toxicity	:	LD50 (Rat): 3,519 mg/kg Target Organs: Central nervous system
Acute toxicity (other routes of administration)	:	LDLo (sheep): 10 mg/kg Application Route: Intravenous

##### **levamisole hydrochloride:**

Acute oral toxicity	:	LD50 (Rat): 180 mg/kg LD50 (Mouse): 223 mg/kg LD50 (Rabbit): 458 mg/kg
Acute inhalation toxicity	:	Remarks: No data available
Acute dermal toxicity	:	Remarks: No data available

##### **Citric acid:**

Acute oral toxicity	:	LD50 (Mouse): 5,400 mg/kg
---------------------	---	---------------------------

**Levamisole / Oxyclozanide Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

||| Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Assessment: The substance or mixture has no acute dermal toxicity

**Sodium metabisulphite:**

||| Acute oral toxicity : LD50 (Rat): 1,540 mg/kg  
Method: OECD Test Guideline 401

||| Acute inhalation toxicity : LC50 (Rat): > 5.5 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist  
Remarks: Based on data from similar materials

||| Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg  
Method: OECD Test Guideline 402  
Remarks: Based on data from similar materials

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Kaolin:**

||| Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**oxyclozanide:**

||| Remarks : Not classified due to lack of data.

**levamisole hydrochloride:**

||| Remarks : No data available

**Citric acid:**

||| Species : Rabbit  
Method : OECD Test Guideline 404  
Result : No skin irritation

**Sodium metabisulphite:**

||| Result : Skin irritation  
||| Remarks : Based on national or regional regulation.

**Serious eye damage/eye irritation**

Not classified based on available information.

# SAFETY DATA SHEET



## Levamisole / Oxyclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

### Components:

#### **Kaolin:**

Species	:	Rabbit
Result	:	No eye irritation

#### **oxyclozanide:**

Remarks	:	Not classified due to lack of data.
---------	---	-------------------------------------

#### **levamisole hydrochloride:**

Remarks	:	No data available
---------	---	-------------------

#### **Citric acid:**

Species	:	Rabbit
Result	:	Irritation to eyes, reversing within 21 days
Method	:	OECD Test Guideline 405

#### **Sodium metabisulphite:**

Species	:	Rabbit
Result	:	Irreversible effects on the eye
Method	:	OECD Test Guideline 405

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

May cause an allergic skin reaction.

#### **Respiratory sensitisation**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

### Components:

#### **oxyclozanide:**

Exposure routes	:	Dermal
Remarks	:	Not classified due to lack of data.

#### **levamisole hydrochloride:**

Remarks	:	No data available
---------	---	-------------------

#### **Sodium metabisulphite:**

Assessment	:	Probability or evidence of skin sensitisation in humans
Remarks	:	Based on national or regional regulation.

Assessment	:	May cause sensitisation by inhalation.
Remarks	:	Based on national or regional regulation.

**Levamisole / Oxyclozanide Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

**Chronic toxicity****Germ cell mutagenicity**

Not classified based on available information.

**Components:****oxyclozanide:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosomal aberration Test system: Human lymphocytes Result: positive
	Test Type: Mouse Lymphoma Result: positive
Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
	Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Application Route: Oral Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

**levamisole hydrochloride:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: Chromosome aberration test in vitro Result: negative

**Citric acid:**

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: in vitro micronucleus test Result: positive
	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
Genotoxicity in vivo	: Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis)

# SAFETY DATA SHEET



## Levamisole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

Species: Rat  
Application Route: Ingestion  
Result: negative

### Sodium metabisulphite:

Genotoxicity in vitro	: Test Type: Bacterial reverse mutation assay (AMES) Result: negative
	Test Type: In vitro mammalian cell gene mutation test Method: OECD Test Guideline 476 Result: negative
Genotoxicity in vivo	: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay) Species: Mouse Application Route: Subcutaneous Method: OECD Test Guideline 474 Result: negative Remarks: Based on data from similar materials

### Carcinogenicity

Not classified based on available information.

### Components:

#### oxclozanide:

Remarks	: Not classified due to lack of data.
---------	---------------------------------------

#### levamisole hydrochloride:

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 80 mg/kg body weight
Remarks	: No significant adverse effects were reported
Species	: Rat
Application Route	: Oral
Exposure time	: 2 Years
NOAEL	: 40 mg/kg body weight
Remarks	: No significant adverse effects were reported

#### Sodium metabisulphite:

Species	: Mouse
Application Route	: Ingestion
Exposure time	: 24 Months
Result	: negative
Remarks	: Based on data from similar materials

**Levamisole / Oxyclozanide Formulation**Version  
5.0Revision Date:  
14.04.2025SDS Number:  
5360102-00013Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019**Reproductive toxicity**

Suspected of damaging the unborn child.

**Components:****oxyclozanide:**

Effects on fertility

: Test Type: Two-generation reproduction toxicity study  
Species: Rat, male and female  
Application Route: Oral  
General Toxicity - Parent: NOAEL: 25 - 35 mg/kg body weight  
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development  
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity - Parent: LOAEL: 75 - 100 mg/kg body weight  
Symptoms: Reduced body weight, No effects on embryofoetal and postnatal development  
Result: No effects on fertility

Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Early Embryonic Development: LOAEL: 75 - 100 mg/kg body weight  
Result: No fetotoxicity, No teratogenic effects

Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
General Toxicity - Parent: LOAEL: 80 - 160 mg/kg body weight  
Result: No fetotoxicity, No teratogenic effects, No effects on fertility

Effects on foetal development

: Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 200 mg/kg body weight  
Result: No fetotoxicity, No teratogenic effects

Test Type: Development  
Species: Rat  
Application Route: Oral  
General Toxicity Maternal: LOAEL: 100 mg/kg body weight  
Result: No fetotoxicity, No teratogenic effects

Test Type: Development  
Species: Rabbit  
Application Route: Oral

**Levamisole / Oxyclozanide Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

Developmental Toxicity: NOAEL: 32 mg/kg body weight  
Result: Fetotoxicity, Skeletal malformations

Reproductive toxicity - Assessment : Suspected of damaging the unborn child.

**levamisole hydrochloride:**

Effects on fertility : Test Type: Three-generation reproduction toxicity study  
Species: Rat  
Application Route: Oral  
Result: No significant adverse effects were reported

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 20 mg/kg body weight  
Result: Fetotoxicity

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Developmental Toxicity: LOAEL: 40 mg/kg body weight  
Result: Fetotoxicity

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

**Citric acid:**

Effects on foetal development : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Sodium metabisulphite:**

Effects on fertility : Test Type: Three-generation study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Ingestion  
Result: negative

**STOT - single exposure**

May cause damage to organs (Central nervous system) if swallowed.

**Components:****oxyclozanide:**

Exposure routes : Oral

# SAFETY DATA SHEET



## Levamisole / Oxyclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

**Target Organs**  
Assessment : Central nervous system  
: May cause damage to organs.

**Citric acid:**  
Assessment : May cause respiratory irritation.

### STOT - repeated exposure

May cause damage to organs (Brain, Liver) through prolonged or repeated exposure.  
May cause damage to organs (Blood, Testis) through prolonged or repeated exposure if swallowed.

### Components:

#### **oxyclozanide:**

**Target Organs**  
Assessment : Brain, Liver  
: May cause damage to organs through prolonged or repeated exposure.

#### **levamisole hydrochloride:**

**Target Organs**  
Assessment : Blood, Testis  
: May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### **oxyclozanide:**

**Species** : Rat  
**NOAEL** : 9 mg/kg  
**LOAEL** : 44.5 mg/kg  
**Application Route** : Oral  
**Exposure time** : 3 Months  
**Target Organs** : Brain, Liver, spleen, Adrenal gland  
**Symptoms** : Liver effects

**Species** : Dog  
**NOAEL** : 5 mg/kg  
**LOAEL** : 25 mg/kg  
**Application Route** : Oral  
**Exposure time** : 3 Months  
**Target Organs** : Brain, Liver  
**Symptoms** : blood effects, alteration in liver enzymes

#### **levamisole hydrochloride:**

**Species** : Rat  
**NOAEL** : 2.5 mg/kg  
**Application Route** : Oral  
**Exposure time** : 18 Months

**Levamisole / Oxclozanide Formulation**

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

|| Target Organs : Testis

|| Species : Dog  
LOAEL : 20 mg/kg  
Application Route : Oral  
Exposure time : 18 Months  
Target Organs : Blood

|| Species : Dog  
LOAEL : 40 mg/kg  
Application Route : Oral  
Exposure time : 3 Months

**Citric acid:**

|| Species : Rat  
NOAEL : 4,000 mg/kg  
LOAEL : 8,000 mg/kg  
Application Route : Ingestion  
Exposure time : 10 Days

**Sodium metabisulphite:**

|| Species : Rat  
NOAEL : 110 mg/kg  
LOAEL : 220 mg/kg  
Application Route : Ingestion  
Exposure time : 104 Weeks

**Aspiration toxicity**

Not classified based on available information.

**Components:****oxyclozanide:**

|| Not applicable

**Experience with human exposure****Components:****oxyclozanide:**

|| Ingestion : Symptoms: May cause, Gastrointestinal disturbance, Central nervous system depression

**levamisole hydrochloride:**

|| Ingestion : Symptoms: Nausea, Vomiting, Headache, Dizziness, hypotension

## Levamisole / Oxclozanide Formulation

Version 5.0 Revision Date: 14.04.2025 SDS Number: 5360102-00013 Date of last issue: 28.09.2024 Date of first issue: 19.12.2019

---

### Section 12: Ecological information

#### Ecotoxicity

##### Components:

###### **oxyclozanide:**

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.69 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
M-Factor (Acute aquatic toxicity)	:	1
M-Factor (Chronic aquatic toxicity)	:	1

###### **levamisole hydrochloride:**

Toxicity to fish	:	LC50 (Oryzias latipes (Japanese medaka)): 37.3 mg/l Exposure time: 96 h Method: OECD Test Guideline 203
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 64 mg/l Exposure time: 48 h Method: OECD Test Guideline 202

###### **Citric acid:**

Toxicity to fish	:	LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 1,535 mg/l Exposure time: 24 h

###### **Sodium metabisulphite:**

Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 178 mg/l Exposure time: 96 h
Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 89 mg/l Exposure time: 48 h
Toxicity to algae/aquatic plants	:	ErC50 (Desmodesmus subspicatus (green algae)): 43.8 mg/l Exposure time: 72 h  EC10 (Desmodesmus subspicatus (green algae)): 33.3 mg/l Exposure time: 72 h
Toxicity to fish (Chronic toxicity)	:	NOEC (Danio rerio (zebra fish)): >= 316 mg/l Exposure time: 34 d Method: OECD Test Guideline 210 Remarks: Based on data from similar materials

# SAFETY DATA SHEET



## Levamisole / Oxyclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC (Daphnia magna (Water flea)): >= 10 mg/l Exposure time: 21 d
Toxicity to microorganisms	:	EC10 (Pseudomonas putida): 30.8 mg/l Exposure time: 17 h

### Persistence and degradability

#### Components:

##### **oxyclozanide:**

Stability in water	:	Hydrolysis: 50 %(156 d) Method: OECD Test Guideline 111
--------------------	---	--

##### **Citric acid:**

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 97 % Exposure time: 28 d Method: OECD Test Guideline 301B
------------------	---	---

### Bioaccumulative potential

#### Components:

##### **oxyclozanide:**

Partition coefficient: n-octanol/water	:	log Pow: 3.99 pH: 7 Method: OECD Test Guideline 107
--	---	---

##### **Citric acid:**

Partition coefficient: n-octanol/water	:	log Pow: -1.72
--	---	----------------

### Mobility in soil

#### Components:

##### **oxyclozanide:**

Distribution among environmental compartments	:	log Koc: 4.83 Method: OECD Test Guideline 106
---	---	--

### Other adverse effects

No data available

---

## Section 13: Disposal considerations

#### **Disposal methods**

Waste from residues	:	Do not dispose of waste into sewer. Dispose of in accordance with local regulations.
---------------------	---	---

# SAFETY DATA SHEET



## Levamisole / Oxyclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

### Section 14: Transport information

#### International Regulations

##### UNRTDG

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxyclozanide)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

##### IATA-DGR

UN/ID No. : UN 3082  
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.  
(oxyclozanide)  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 964  
Packing instruction (passenger aircraft) : 964  
Environmentally hazardous : yes

##### IMDG-Code

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxyclozanide)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### National Regulations

##### NZS 5433

UN number : UN 3082  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.  
(oxyclozanide)  
Class : 9  
Packing group : III

# SAFETY DATA SHEET



## Levamisole / Oxclozanide Formulation

Version 5.0      Revision Date: 14.04.2025      SDS Number: 5360102-00013      Date of last issue: 28.09.2024  
Date of first issue: 19.12.2019

---

Labels : 9  
Hazchem Code : 3Z  
Marine pollutant : no

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

---

## Section 15: Regulatory information

### Safety, health and environmental regulations/legislation specific for the substance or mixture

#### HSNO Approval Number

HSR100759 Veterinary Medicines Non dispersive Open System Application Group Standard

Tolerable Exposure Limits (TEL)

Not applicable

Environmental Exposure Limits (EEL)

Not applicable

#### HSW Controls

Certified handler certificate not required.

Tracking hazardous substance not required.

Refer to the Health and Safety at Work (Hazardous Substances) Regulations 2017, for further information.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

---

## Section 16: Other information

Revision Date : 14.04.2025

#### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : dd.mm.yyyy

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

# SAFETY DATA SHEET



## Levamisole / Oxclozanide Formulation

---

Version 5.0	Revision Date: 14.04.2025	SDS Number: 5360102-00013	Date of last issue: 28.09.2024 Date of first issue: 19.12.2019
----------------	------------------------------	------------------------------	---

---

NZ OEL : New Zealand. Workplace Exposure Standards for Atmospheric Contaminants

ACGIH / TWA : 8-hour, time-weighted average

NZ OEL / WES-TWA : Workplace Exposure Standard - Time Weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NZ / EN